Role of cytokine therapy for renal cell carcinoma in the era of targeted agents

Current Oncology

Volumn 16, Issue S1, 2009, Pages S40-S44

  Koneru, R ^a   Hotte, Sebastien J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

cytokines; interferon; interleukin 2; Renal cancer; therapy

Indexed keywords

EID: 84855294645     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i0.417     Document Type: Article

References (26)

1. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177–86.
2. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128–31.
3. Kurzrock R, Talpaz M, Gutterman JU. Interferons: basic principles and preclinical studies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott; 1991: 247–74.
4. Fosså SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000;27:187–93.
5. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;:CD001425.
6. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immuno-therapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000;:CD001425.
7. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283–95.
8. Hancock B, Griffiths G, Ritchie A, on behalf of the mrc Renal Cancer Collaborators. Updated results of the mrc randomised controlled trial of alpha interferon vs. mpa in patients with metastatic renal carcinoma [abstract 1336]. Proc Am Soc Clin Oncol 2000;19:. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_ detail_view&confID=2&abstractID=201403; cited February 11, 2009]
9. Medical Research Council Renal Cancer Collaborators. Inter-feron-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14– 17.
10. Negrier S, Perol D, Ravaud A, et al., and the French Im-munotherapy Intergroup. Do cytokines improve survival in patients with metastatic renal cell carcinoma (mrcc) of intermediate prognosis? Results of the prospective randomized percy Quattro trial [abstract 4511]. Proc Am Soc Clin Oncol 2005;23:. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_ detail_view&confID=34&abstractID=31254; cited February 11, 2009]
11. Dexeus FH, Logothetis CJ, Sella A, Finn L. Interferon alternat-ing with chemotherapy for patients with metastatic renal cell carcinoma. Am J Clin Oncol 1989;12:350–4.
12. Dutcher JP, Fine JP, Krigel RL, et al. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase ii study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 2003;20:271–81.
13. Foon K, Doroshow J, Bonnem E, et al. A prospective randomized trial of alpha 2b-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988;7:540–5.
14. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995;45:758–62.
15. Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblas-tine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859–67.
16. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990;29:155–62.
17. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Pop-pel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.
18. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865–75.
19. Hotte S, Waldron T, Canil C, Winquist E. Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Can Urol Assoc J 2007;1:27–38.
20. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase ix expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714–21.
21. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2– and interferon alfa-2a–based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (dgcin). J Clin Oncol 2004;22:1188–94.
22. Atzpodien J, Kirchner H, Illiger HJ, et al. il-2 in combination with ifn-alpha and 5-fu versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85:1130–6.
23. Rini BI, Halabi S, Rosenberg JE, et al. calgb 90206: a phase iii trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract 350]. Proc Genitourin Cancers Symp 2008;:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=54&abstrac tID=20357; cited February 11, 2009]
24. Escudier B, Pluzanska A, Koralewski P, et al. on behalf of the avoren Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 2007;370:2103–11.
25. Hudes G, Carducci M, Tomczak P, et al. on behalf of the Global arcc Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.
26. Gordon MS, Manola J, Fairclough D, et al. Low dose interferon-α2b (ifn) + thalidomide (t) in patients (pts) with previously untreated renal cell cancer (rcc). Improvement in progression-free survival (pfs) but not quality of life (qol) or overall survival (os). A phase iii study of the Eastern Cooperative Oncology Group (E2898) [abstract 4516]. Proc Am Soc Clin Oncol 2004;22:386s. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_ detail_view&confID=26&abstractID=3808; cited February 11, 2009]